Aeolus announces positive results of mustard gas treatment study
The studies, which were conducted by researchers from the U.S. Army Medical Research Institute for Chemical Defense, the University of Colorado and National Jewish Health, were the third and fourth studies to confirm the protective benefits of AEOL 10150. The studies found AEOL 10150 provided significant lung protection and significantly improved survival in rats exposed to whole mustard gas.
"AEOL 10150 continues to demonstrate significant protective effects in rescuing the lung against the deleterious effects of sulfur mustard vapor resulting in major improvements in survival and lung function," Brian Day, the chief science officer of Aeolus Pharmaceuticals, said. "These data affirm our earlier studies where AEOL 10150 protected the lung against sulfur mustard and the half-mustard, 2-chloroethyl ethylsufide."
There are no approved and effective treatments for mustard gas exposure. The National Institutes of Health CounterACT program awarded a sponsored research grant to the University of Colorado and National Jewish Health to develop an effective treatment. Mustard gas exposure can cause respiratory injury, blistering of the skin, fibrosis and death.
Aeolus Pharmaceuticals plans to meet with the U.S. Food and Drug Administration to determine a pivotal trial design and to determine an acceptable second species for approval under the animal rule.
"This study confirms AEOL 10150's potential as an effective countermeasure for mustard gas exposure," John McManus, the president and CEO of Aeolus Pharmaceuticals, said. "Given the dramatic improvements in survival and reductions in lung damage that we have seen in this and former studies, Aeolus plans to meet with the FDA to discuss the design of a pivotal study in rats, and an appropriate second species to satisfy the requirements for approval under the animal rule. We are also grateful to NIH CounterACT for their support of this program, and to Dr. Day and Dr. Carl White, who have provided great leadership to this program."
Aeolus Pharmaceuticals presented the data at the 7th Annual CounterACT Countermeasures Against Chemical Threats Network Research Symposium in Washington.